Healthcare / BiotechnologyNasdaqGM
$4.50
-1.28 (-22.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-49.3M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$291M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-25.6%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-56.0M · FCF $-45.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | $316952.00 | $2.1M | $2.3M |
| Net Income | $-56.0M | $-56.0M | $-61.0M | $-53.5M | $-50.5M | $-33.5M | $-17.0M |
| EBITDA | $-59.0M | $-59.0M | $-63.7M | $-58.1M | $-51.5M | — | — |
| EPS | — | — | -2.04 | -1.88 | -1.91 | -2.46 | -3.44 |
| Gross Margin | — | — | — | — | 50.1% | 44.6% | 44.6% |
| Operating Margin | — | — | — | — | -16325.9% | -1629.2% | -739.0% |
| Net Margin | — | — | — | — | -15937.3% | -1612.3% | -737.2% |
| Balance Sheet | |||||||
| Debt/Equity | 0.02 | 0.02 | 0.10 | 0.05 | 0.04 | — | — |
| Current Ratio | 32.45 | 32.45 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-45.5M | $-45.5M | $-55.1M | $-49.3M | $-44.8M | $-30.9M | $-14.7M |
| Returns | |||||||
| ROE | -25.6% | -25.6% | -147.5% | -59.0% | -46.0% | -21.5% | 75.8% |
| Valuation | |||||||
| P/B | 1.33 | 1.33 | 1.70 | 2.05 | 0.95 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | — | — | — | — | — | -10.0% | — |
| EPS Growth | — | — | -8.5% | 1.6% | — | 28.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+162.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.04 → n/d
Residual
+162.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.